### "Type I interferon potentiates humoral immunity in the nasal mucosa": Supplementary material

Diego R. Hijano<sup>1</sup>, David T. Siefker<sup>2</sup>, Bishwas Shrestha<sup>2</sup>, Sridhar Jaligama<sup>2</sup>, Luan D Vu<sup>2</sup>, Heather Tillman<sup>3</sup>, David Finkelestein<sup>4</sup>, Jordy Saravia<sup>2</sup>, Dahui You<sup>2</sup>, and Stephania A. Cormier<sup>2,5,\*</sup> <sup>1</sup>Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee <sup>2</sup>Department of Pediatrics, University of Tennessee Health Science Center, Memphis,

Tennessee

<sup>3</sup>Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee

<sup>4</sup>Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee

<sup>5</sup>Children's Foundation Research Institute, Memphis, Tennessee

#### **Supplementary Figure 1: Gating strategy**

#### Supplementary Figure 2 (related to Figure 1):

(A) Venn diagram for the numbers of common and specific genes in NALT of neonatal mice that received IFN- $\alpha$  (INR) compared to those that received media (NR) or were depleted of B cells prior to RSV infection. (B) Description of GSEA analysis plot. (C) GSEA comparison for INR and NR NALT for granulocyte migration, neutrophil immunity, regulation of T cell proliferation and MAPK activity. (D) Volcano plot showing significance versus fold change of gene expression of neonatal mice that received IFN- $\alpha$  (INR) vs neonatal mice that received palivizumab. (E) Principal component analysis of lung gene expression of neonatal mice that received IFN- $\alpha$  (INR) vs neonatal mice that received IFN- $\alpha$  (INR) compared to those that received media (NR) or were depleted of B cells prior to RSV infection. (F) *NS1* gene expression in lungs from RSV-infected adult (gray) and neonatal mice receiving IFN- $\alpha$  (IRN/red), placebo (NR/blue), or anti CD-20 (green) 16 h before infection. n=3-5; N=2 \**P* < 0.05, \*\**P* < 0.01

#### Supplementary Figure 3 (related to Figure 1):

Percentage of inflammation in lungs from RSV-infected neonatal mice receiving IFN- $\alpha$  (INNR/maroon) or placebo (INR/blue) 16 h before infection. Controls were inoculated with media (black). n=3-5; N=2 \*P < 0.05, \*\*P < 0.01

#### Supplementary Figure 4 (related to Figure 5):

Intracellular IgA positive cells by flow cytometry in NALT and lungs from adult (ARR) and neonatal mice that received IFN-  $\alpha$  (INRR) or placebo (NRR) 24 hrs. prior to RSV infection, reinfected 4 weeks after primary infection (A-C). Intracellular IgA. (A) Representative flow cytometry panels of B220+CD19+IgA+ cells. (B) Percentage of B220+CD19+IgA+ 7 days post-secondary infection in NALT; (C) Percentage of B220+CD19+IgA+ 7 days post-secondary infection in lung. n=3-5; N=2

#### **Supplementary Figure 5 (related to Figure 6):**

RSV specific mucosal IgA in the respiratory tract.

(A-C) RSV specific mucosal IgA at 21 days post-infection different time points from RSV infected adult (AR) and neonatal mice (NR). Age matched controls for adult (AS) and neonatal (NS) mice. (A) NALT; (B) Bronchoalveolar lavage; (C) Lungs homogenates. Dotted line represents lower limit of detection of the assay. n=3-5; N=2

#### **Supplementary Figure 6:**

Animal model, animal groups and different interventions used for the experiment described in the manuscript.



Live/Dead Near IR- Molecular Probes - L34975

BAFFR+









21 days post-infection



Gene Symbol	INR (mean)*	Palivizumab (mean)*	p value	Log FC	FDR
Xcl1	4.001560211	6.04968977	0.0255268	-2.0481296	0.03022062
Clec4g	3.353630066	5.893539906	0.00045433	-2.5399098	0.00138147
Dusp18	4.388689995	6.587800026	0.00311915	-2.19911	0.00520468
Dusp10	7.815410137	10.32989979	0.00464768	-2.5144897	0.00706941
Dusp9	3.607120037	6.599470139	0.00010193	-2.9923501	0.00060953
Dusp7	6.849430084	9.331230164	0.00035158	-2.4818001	0.00118886
Lax1	4.186950207	6.705649853	0.00328686	-2.5186996	0.00540932

**Supplementary Table 1**: Expression of genes involved in regulation of the inflammatory response.

\*Results are expressed as means of 4 mice per group.

Gene Symbol	INR (mean)*	Palivizumab (mean)*	p value	Log FC	FDR
Cklf	6.052740097	9.923999786	3.6649E-05	-3.8712597	0.00038382
Pde4b	7.904960155	10.0934	0.00021007	-2.1884398	0.00088198
C5ar1	3.90557003	6.657660007	4.1685E-07	-2.75209	0.00012179
Trem1	3.987540007	6.51928997	0.00040153	-2.53175	0.0012811
Edn2	3.812589884	5.981460094	4.1943E-05	-2.1688702	0.00040904
ll1b	4.342830181	7.820879936	5.0005E-06	-3.4780498	0.00019068
S100a8	7.316649914	10.30179977	0.00582763	-2.9851499	0.00850084
Csf3r	5.02891016	7.486780167	0.00026783	-2.45787	0.00101522
Ccl20	4.560780048	6.678880215	0.00780663	-2.1181002	0.01078206
Cxcl5	3.230870008	5.669290066	5.2339E-05	-2.4384201	0.00044859

**Supplementary Table 2**: Expression of genes involved in granulocyte and neutrophil migration.

\*Results are expressed as means of 4 mice per group.

Gene Symbol	INR (mean)*	Palivizumab (mean)*	p value	Log FC	FDR
lfna1	4.18671989	6.765270233	2.2696E-05	-2.5785503	0.00031633
lfna2	3.32118011	6.461239815	0.00013454	-3.1400597	0.00070665
Ifna5	5.24568987	7.683740139	1.7437E-05	-2.4380503	0.00028263
lfna6	3.72046995	6.45333004	0.00010143	-2.7328601	0.00060952
lfna7	4.06274986	7.142149925	8.8788E-05	-3.0794001	0.00057018
lfna11	2.98958993	5.263639927	0.00053228	-2.27405	0.00153147
lfna14	3.24411988	5.841479778	4.226E-06	-2.5973599	0.00018788
lfna16	3.52806997	6.228750229	3.9546E-05	-2.7006803	0.00039934
Tnfsf13b	4.44101	6.717189789	0.00376091	-2.2761798	0.00600049

**Supplementary Table 3**: IFN- $\alpha$  and Tnfsf13b (BAFF) gene expression.

\*Results are expressed as means of 4 mice per group.